Five per cent heat treated stable plasma protein solution (S PPS) has been rapidly infused into 25 patients, as fluid replacement during large volume plasmapheresis. Reactions were produced in 20 patients. Subjective symptoms of flushing, nasal stuffiness, fullness and throbbing in the head, colicky abdominal pain, metallic taste or apprehension were observed in 16 patients, and 11 patients became hypotensive with an average systolic pressure of 70 mm Hg. These observations support earlier reports of hypotension due to rapid SPPS infusion, and document the occurrence of subjective symptoms which may be the harbingers of a hypotensive reaction. In view of the known presence of a bradykinin-like substance in some heat treated plasma protein solutions, hypotension during S PPS infusion should be interpreted with caution in the light of these findings.
INTRODUCTION
Recent years have seen a marked increase in the use of five per cent heat treated plasma protein solutions for volume replacement. The advantages of such solutions are considerable, especially for plasma exchange, but there has been little mention of any possible hazards associated with their use. The introduction of blood cell separators into clinical medicine has facilitated large volume plasma exchange. Plasmapheresis is of established value in hyperviscosity syndromes secondary to paraproteinaemia, but recent studies (Isbister et al. 1975) suggest it may be of value in the management of other conditions. Replacement fluids for large volume plasmapheresis were initially restricted to group specific fresh frozen or dried plasma, but experience has shown that various protein and electrolyte substitutes may be used without clinically significant changes in coagulation, electrolytes or plasma proteins. There are several disadvantages in confining fluid replacement to fresh frozen plasma; allergic reactions are common, supply of adequate amounts of group specific plasma may be difficult and hypocalcaemia may occur. Bayer et al. (1974) showed that plasma removed during large volume plasmapheresis could be replaced totally by plasma substitutes, devoid of coagulation factors, without significant coagulation disturbance.
The purpose of this communication is to bring attention to the frequency of reactions to plasma protein solutions when infused rapidly during large volume plasmapheresis.
MATERIALS AND METHODS
The continuous flow blood cell separator (Celltrifuge-Aminco) has been used for plasmapheresis. This is a vein to vein system with the venous blood circulating through a centrifuge bowl spinning at 1200 rpm. The plasma layer is removed and collected into large plastic bags. An average of four litres is removed and replaced with a combination of saline, Hartmann's solution, Haemaccel, Stable Plasma Protein Solution (SPPS) or Normal Serum Albumin (NSA) and fresh frozen plasma.
RESULTS
A total of 150 plasma exchanges have been performed on 32 different patients for a wide range of conditions (Isbister et al. 1975) . Hyperviscosity due to paraproteinaemia and immune diseases have been the commonest indications. During an average exchange of four litres the plasma is replaced with 1,000 ml Hartmann's solution, 1,000 ml Haemaccel. 1,500 ml plasma protein substitute (SPPS or NSA) and 500 ml fresh frozen plasma; the procedure takes a total of 2-3 hours. Occasional vasovagal reactions respond rapidly to intravenous atropine and mild thrombocytopenia may occur which i,; not clinically significant. Hypothermia is avoided by warming the return line and symptoms of hypocalcaemia are not a problem if the fresh frozen plasma is infused slowly.
Several unexplained episodes of severe hypotension occurred during early plasmapheresis procedures. These hypotensin' episodes were usually associated with tachycardia and failed to respond to atropine but recovered on cessation of SPPS infusion and rapid administration of Hartmann's solution. Since these initial experiences, all patients receiving SPPS as plasma replacement have been observed closely.
Of ::t! patients undergoing plasmapheresis, 25 were given varying volumes of SPPS infused at a rate of :!0-40 ml/minute. All patients were fully conscious during the procedure and able to report any symptoms they noticed. Twenty (8()lYo) patients had some kind of adverse reaction. Sixteen (64 CJo) complained of subjective symptoms after the infusion of 100-500 ml of SPPS. "Kasal stuffiness, fullness and throbbing in the head, flushing, colicky abdominal pain, mciallic taste and apprehension were the commonest symptoms. Five of these patients subsequently developed hypotension.
These symptoms were rapidly relieved following cessation of the infusion. In thos(' cases rechallenged with Sl'PS these s.vmptoms consistently recurred. Five (:!O(~ ()) patients developed severe lower lumbar pain following SPPS infusion which resolved over several minutes when administration was stopped. Two of these patients were rechallenged with SPPS and the same reaction rpcurred. Eleven (44%) patients developed hypotension following SPPS, usually with associated faintness or syncope. Minor degrees of hypotension were not possible to monitor by sphygmomanometry in view of the vein to vein continuous flow system. Systolic blood pressure measurements in the 11 cases following SPPS infusion ranged from 40-90 mm Hg. The average level was 70 mm Hg which represented an average fall of 45% from pre-infusion levels. In one case there was peripheral circulatory collapse for a brief time with impalpable peripheral pulses. Recovery was rapid in all cases of hypotension following cessation of the SPPS and rapid infusion of Hartmann's solution.
All patients having reactions to SPPS have subsequently been given concentrated albumin diluted in Hartmann's ~olution, without any complications. Haemaccel was associated with reactions in a small number of cases; shivering (~), pruritus and urticaria (3). Reactions to fresh frozen plasma, routinely administered at the conclusion of the plasmapheresis are frequent. These are usually of a mild allergic nature with urticaria or fever.
DlSCt;SSIO~
Fiw per cent heat treated plasma protein solutions are being used increasingly in clinical medicine as volume replacement. Stability, sterility and apparent freedom from reactions have encouraged their greater use. Initial studies in cats (Hink et al. 1957 ) demonstrated a mild vasodepressor activity but this was not considered to be of clinical importance. , Harrison, Torda and Schiff (1971) and Torda et al. (1H73) , noted a :!()-oO per cent drop in blood pressure in patients on cardiopulmonary bypass following the rapid infusion of SPPS. Bland et al. 1972 observed similar hypoten~ion following commercially available five per cent plasma protein solution (Plasmatein) infused at :!;) mljminute. SUbjective s~"mptoms in conscious patients have not been documented previously.
Thi~ study c()nti.rll1~ that the rapid intran~nous infusion of SPPS is commonly associated with mild to se\"ere hypotelision. Subjecti\"e symptoms of llasal stuffiness, flushing, fullness and throbbing in the head, apprehension, metallic taste, cnlick~" abdominal pain and back pain have led to the cessation of the infusion of these patients, presumabh" a\'oiding the development of hypotension. As the patients are fully conscious and co-operatiH" plasmapheresis offers an ideal situation in which to monitor the effect of rapid infusion of SPPS and reactions can be easily related to the infusion. Izaka et al. (1974) have isolated a bradykininlike substance from heat treated human plasma protein solutions. This fraction consistently causes hypotension in dogs. These workers have also demonstrated a kininogen-like substance in unheated human plasma proteins. It appears that heating during the preparation of the protein solution generates this vasodepressor bradykinin-like activity from the kininogen-like substance in the unheated fraction. Slow infusion of SPPS does not seem to be associated with hypotension, presumably due to rapid inactivation of the vasodepressor Anaesthesia and Intensive Care, "al. IV, No.:d, JJay, 1!J76 in the pulmonary circulation. The apparent sensitivity of patients on cardio-pulmonary bypass to rapid SPPS infusion may be due to a delayed inactivation of this bradykinin-like substance. Most of the objective symptoms observed in these patients could be attributed to a bradykinin-like substance, as bradykinin is known to be a potent vasodilator, contractor of smooth muscle and pain producer.
As SPPS is frequently used for rapid volume replacement these observations are of considerable clinical importance. Not only may vasodepressor effects be deleterious in the volume-depleted patient, but hypotension due to SPPS may be wrongly interpreted.
Further investigations are being undertaken to investigate the vasodepressor effect of SPPS, but it has been the aim of this preliminary report to support the previous observations that rapid infusion of SPPS may cause hypotension and also to bring attention to subjective symptoms that may occur in the conscious patient.
